Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship

Equity Neuroscience · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles